Earnings Call Summary | Coherus BioSciences(CHRS.US) Q4 2023 Earnings Conference
Earnings Call Summary | Coherus BioSciences(CHRS.US) Q4 2023 Earnings Conference
The following is a summary of the Coherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call Transcript:
以下是Coherus BioSciences, Inc.（CHRS）2023年第四季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Coherus BioSciences reported Q4 combined net product revenue of $91.4 million, a 23% increase over Q3, with full-year net product revenue for 2023 being $256.6 million, a 22% increase over 2022.
UDENYCA revenue grew in Q4 with net sales of $36.2 million, a quarterly increase of 10%.
Q4 sales of CIMERLI generated $2.2 million, while the full-year 2023 sales were $3.6 million.
LOQTORZI recorded sales of $600,000 in Q4, based on initial wholesaler stocking for commercial launch.
The net loss for Q4 2023 was $79.7 million or $0.71 per share, compared to a net loss of $58.9 million or $0.76 per share for the same period in 2022.
Coherus ended the year with cash and cash equivalents of $117.7 million, compared to $192 million at the end of 2022.
Cost of goods sold (COGS) increased to $159 million in 2023, up from $70.1 million in 2022.
R&D expenses declined to $109.4 million. SG&A expenses decreased to $192 million for 2023, from $198.5 million in 2022.
Coherus BioSciences报告称，第四季度合并净产品收入为9,140万美元，比第三季度增长23％，2023年全年净产品收入为2.566亿美元，比2022年增长22％。
UDENYCA收入在第四季度增长，净销售额为3620万美元，季度增长10％。
CIMERLI第四季度的销售额创造了220万美元，而2023年全年销售额为360万美元。
根据批发商最初的商业上市库存，LOQTORZI在第四季度的销售额为60万美元。
2023年第四季度的净亏损为7,970万美元，合每股亏损0.71美元，而2022年同期的净亏损为5,890万美元，合每股亏损0.76美元。
Coherus年底的现金及现金等价物为1.177亿美元，而2022年底为1.92亿美元。
商品销售成本（COGS）从2022年的7,010万美元增加到2023年的1.59亿美元。
研发费用降至1.094亿美元。销售和收购支出从2022年的1.985亿美元降至2023年的1.92亿美元。
Business Progress:
业务进展：
The company received timely FDA approval for UDENYCA and LOQTORZI for all lines of therapy in nasopharyngeal carcinoma.
Coherus published numerous positive phase 3 data sets for its drug, LOQTORZI, across various tumor types.
The company is currently enrolling patients for further investigation of casdozokitug in combination with toripalimab.
Coherus plans to strengthen its position in the market by offering three unique product options of UDENYCA to meet different needs.
For 2024, the company aims to achieve market share growth and profitability focusing on oncology products, particularly UDENYCA and LOQTORZI.
Coherus is also progressing with LOQTORZI, its treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). Since its launch on January 2, 2023, 59 accounts have ordered LOQTORZI.
In 2024, the company plans to further reduce costs, decrease headcount, and divest non-core assets to achieve a sustainable growth path.
The company also plans to submit an IND for its anti-ILT4 antibody program, CHS-1000, in Q2 of 2024.
The company announced that UDENYCA sold 1 million units since its launch, representing a significant milestone.
该公司及时获得了美国食品药品管理局的批准，允许UDENYCA和LOQTORZI用于鼻咽癌的所有疗法。
Coherus发布了许多不同肿瘤类型的药物LOQTORZI的3期阳性数据集。
该公司目前正在招收患者进一步研究casdozokitug与托瑞帕利单抗联合用药的情况。
Coherus计划通过提供三种独特的UDENYCA产品选项来巩固其在市场上的地位，以满足不同的需求。
2024年，该公司的目标是实现市场份额增长和盈利能力，重点是肿瘤产品，尤其是UDENYCA和LOQTORZI。
Coherus在治疗复发性或转移性鼻咽癌（NPC）的LOQTORZI方面也取得了进展。自 2023 年 1 月 2 日推出以来，已有 59 个账户订购了 LOQTORZI。
2024年，该公司计划进一步降低成本，减少员工人数，剥离非核心资产，以实现可持续增长之路。
该公司还计划在2024年第二季度提交其抗ILT4抗体计划 CHS-1000 的临床试验报告。
该公司宣布，UDENYCA自推出以来已售出100万台，这是一个重要的里程碑。
More details: Coherus BioSciences IR
更多详情： Coherus 生物科学红外线
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。